UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

Quarterly Report Pursuant to Section
13 or 15(d)

of the Securities Exchange Act of 1934



For the Quarterly Period Ended September
30, 2011



Commission File Number: 1-13441



HEMISPHERX BIOPHARMA, INC.

(Exact name of registrant as specified in
its charter)



|Delaware                        |  | 52-0845822         
|------------------------------- |  | -------------------
|(State or other jurisdiction of |  | (I.R.S. Employer   
|incorporation or organization)  |  | Identification No.)



1617 JFK Boulevard, Suite 500, Philadelphia,
PA 19103

(Address of principal executive offices)
(Zip Code)



(215) 988-0080

(Registrant's telephone number, including
area code)



(Former name,
former address and former fiscal year, if changed since last report)



Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

x
Yes  ̈ No



Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter
period that the registrant was required to submit and post such files).

xYes  ̈ No



Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of
“large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act. (Check one):



| ̈Large accelerated filer | xAccelerated filer        
|------------------------ | --------------------------
| ̈Non-accelerated filer   |  ̈Smaller reporting company



Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ̈ Yes x
No



135,566,471 shares of common stock were outstanding as of November
1, 2011.











EXPLANATORY NOTE



This Amendment No. 1 to the Form 10-Q
(this “Amendment”) amends the Quarterly Report on Form 10-Q of Hemispherx Biopharma, Inc. for the period ended September 30,
2011 filed on November 9, 2011 (the “Form 10-Q”) for the sole purpose of refiling Exhibit 10.1 & 10.2 (certain
portions of which were previously omitted pursuant to a confidential treatment order granted by the Securities and Exchange Commission
(the “SEC”)) and in connection therewith, to amend Part II, Item 6 of the Form 10-Q and the Exhibit Index to the
Form 10-Q. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, Item 6 of Part II of the Form 10-Q
also has been amended to contain currently dated certifications from our Chief Executive Officer and Chief Financial Officer. The
currently dated certifications are attached hereto as Exhibits 31.1 and 31.2. Because no financial statements of Hemispherx Biopharma,
Inc. are contained in this Amendment, we are not including certifications pursuant to 18 U.S.C. 1350.



No other changes, other than described
above, are made to the Form 10-Q other than to update the cover page of the Form 10-Q to reflect that it is an amendment to the
Form 10-Q. Unless expressly stated, this Amendment does not reflect events occurring after the filing of the Form 10-Q, nor does
it modify or update in any way the disclosures contained in the Form 10-Q. Accordingly, this Amendment should be read in conjunction
with the Form 10-Q and our other filings made with the SEC subsequent to the filing of the Form 10-Q.











ITEM 6: Exhibits



| | (a) | Exhibits
| | --- | --------



|10.1 |  | Vendor Agreement with Bio Ridge Pharma, LLC, effective on August 15, 2011 and executed on September 6, 2011.       
|---- |  | -------------------------------------------------------------------------------------------------------------------
|     |  |                                                                                                                    
|10.2 |  | Vendor Agreement with Armada Healthcare, LLC, effective and executed on September 6, 2011.                         
|     |  |                                                                                                                    
|31.1 |  | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company's Chief Executive Officer.
|     |  |                                                                                                                    
|31.2 |  | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company's Chief Financial Officer.



-3-







SIGNATURES



Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



|                       | HEMISPHERX BIOPHARMA, INC.         
|---------------------- | -----------------------------------
|                       |                                    
|                       | /s/ Thomas K. Equels               
|                       | Thomas K. Equels, Esq.             
|                       | Chief Executive Officer & President
|                       |                                    
|                       | /s/ Adam Pascale                   
|                       | Adam Pascale                       
|                       | Chief Financial Officer            
|                       |                                    
|Date: January 13, 2017 |                                    



-4-